Evidence map›Paper›PMID 26417293›Full record

ArticleEXCLI journal2014

Mutant p53 protein expression and antioxidant status deficiency in breast cancer.

Zorka Milicevic, Jelena Kasapovic, Ljubica Gavrilovic, Zorka Milovanovic, Vladan Bajic, Biljana Spremo-Potparevic

Open access · greenAbstract read
In one paragraph

Article in EXCLI journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zorka MilicevicLaboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia.
Jelena KasapovicLaboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia.
Ljubica GavrilovicLaboratory of Molecular Biology and Endocrinology, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia.
Zorka MilovanovicNational Center of Cancer Research (NCRC), Institute for Oncology and Radiology of Serbia, Pasterova 14, 11 000 Belgrade, Serbia.
Vladan BajicDepartment for Radiobiology and Molecular Genetics, "Vinca" Institute of Nuclear Sciences, Mihaila Petrovica Alasa 12-14, University of Belgrade, 11 001 Belgrade, Serbia.
Biljana Spremo-PotparevicDepartment of Biology and Human Genetics, Institute of Physiology, Faculty of Pharmacy, Vojvode Stepe 450, University of Belgrade, 11 000 Belgrade, Serbia.
University of Belgrade · RSOncology Institute of Vojvodina · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitopespecific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Δp53 (45 kDa) and isoform of ~ 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p<0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p<0.001; catalase, CAT, p<0.01; glutathione reductase, GR, p<0.001; glutathione, GSH, p<0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p<0.05 ) and lowered antioxidant activity of CAT (- 0.437, p<0.01) in the breast cancer patients.

Indexed as

antioxidantsbreast carcinomalipid peroxidationp53

Identifiers

PMID26417293
PMCPMC4464499
OpenAlexW2306445224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.